Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.71 – $17.40
20% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $318.0K | $530.0K | $623.0K | $1.7M | $752.0K | $2.3M | $2.6M | $2.6M |
| Cost of revenue | $158.0K | $249.0K | $409.0K | $925.0K | $585.0K | $746.0K | $1.1M | $2.4M |
| Gross profit | $160.0K | $281.0K | $214.0K | $770.0K | $167.0K | $1.5M | $1.5M | $153.0K |
| Gross margin | 50.3% | 53.0% | 34.3% | 45.4% | 22.2% | 67.3% | 59.0% | 6.0% |
| R&D | $614.0K | $514.0K | $171.0K | $293.0K | $283.0K | $185.0K | $909.0K | $1.8M |
| Operating income | −$4.3M | −$5.2M | −$4.7M | −$5.7M | −$5.0M | −$3.4M | −$3.6M | −$22.9M |
| EBITDA | −$4.3M | −$5.7M | −$4.2M | −$14.2M | −$5.4M | −$3.5M | −$3.7M | $897.0K |
| Net income | −$4.2M | −$5.8M | −$4.3M | −$14.3M | −$5.4M | −$3.7M | −$3.7M | −$18.2M |
| Net margin | -1306.3% | -1093.2% | -694.4% | -842.6% | -724.5% | -162.5% | -144.8% | -712.3% |
| EPS (diluted) | -128.80 | -167.00 | -84.00 | -113.50 | -38.40 | -21.20 | -13.73 | -28.93 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $229000 | $-1914.00 | $-1914.00–$-1914.00 | 1 |
| 2027 | $379000 | $-1364.00 | $-1364.00–$-1364.00 | 1 |
| 2028 | $627000 | $-2090.00 | $-2090.00–$-2090.00 | 1 |
| 2029 | $1M | $-1782.00 | $-1782.00–$-1782.00 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds NAOV.
No tracked institution reports a position in NAOV as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-03-14 | 1-for-11reverse |
| 2023-02-09 | 1-for-20reverse |
No one on the platform has traded NAOV yet.
| $653099 |
| — |
| CNSPCNS Pharmaceuticals, Inc. | $4.15 | +4.27% | $2M | — |
| GRIGRI Bio, Inc. | $1.86 | +2.20% | $167088 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.4× sales vs its 2.6× historical median P/S.
Fair value ≈ $24.62 · price $4.02 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Focusing on early-stage momentum before the crowd: $RZLV $BCTX Looking for: ✔️ Volume expansion ✔️ Break + hold ✔️ VWAP reclaim These are the types that can move fast when they trigger. Not chasing — waiting for confirmation. $IXHL $SOUN $NAOV
View on StockTwits ↗$NAOV NanoVibronix develops ultrasound-based medical devices. Revenue growth depends on adoption and distribution expansion. Liquidity risk remains high.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.